Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions

Alzheimer's and Dementia

Volumn 11, Issue 9, 2015, Pages 1110-1120

  Varley, James ^a   Brooks, David J ^a   Edison, Paul ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Dementia; Microglial activation; MRI; Neurodegenerative disease; neuroinflammation; PET; TSPO

Indexed keywords

BIOLOGICAL MARKER; CARRIER PROTEIN; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; ARTICLE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; HUMAN; HUNTINGTON CHOREA; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; IMMUNOLOGY; IMMUNOMODULATION; PHYSIOLOGY; SCINTISCANNING;

ANIMALS; BRAIN; CLINICAL TRIALS AS TOPIC; DEMENTIA; HUMANS; NEUROIMMUNOMODULATION; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS;

EID: 84942191110     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.08.105     Document Type: Review

References (118)

1. P.L. McGeer, S. Itagaki, B.E. Boyes, and E.G. McGeer Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 38 1988 1285 1291
2. R.E. Mrak, and W.S. Griffin Common inflammatory mechanisms in Lewy body disease and Alzheimer disease J Neuropathol Exp Neurol 66 2007 683 686
3. R.M. Liscic Frontotemporal dementias: update on recent developments in molecular genetics and neuropathology Arh Hig Rada Toksikol 60 2009 117 122
4. E. Sapp, K.B. Kegel, N. Aronin, T. Hashikawa, Y. Uchiyama, K. Tohyama, and et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain J Neuropathol Exp Neurol 60 2001 161 172
5. M. Sastre, J. Walter, and S.M. Gentleman Interactions between APP secretases and inflammatory mediators J Neuroinflammation 5 2008 25
6. T. Wyss-Coray, and L. Mucke Inflammation in neurodegenerative disease - a double-edged sword Neuron 35 2002 419 432
7. P.L. McGeer, and E.G. McGeer Inflammation and the degenerative diseases of aging Ann N Y Acad Sci 1035 2004 104 116
8. M.E. Tremblay The role of microglia at synapses in the healthy CNS: novel insights from recent imaging studies Neuron Glia Biol 7 2011 67 76
9. A. Sierra, J.M. Encinas, J.J. Deudero, J.H. Chancey, G. Enikolopov, L.S. Overstreet-Wadiche, and et al. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis Cell Stem Cell 7 2010 483 495
10. L. Fetler, and S. Amigorena Neuroscience. Brain under surveillance: the microglia patrol Science 309 2005 392 393
11. D.W. Dickson, S.C. Lee, L.A. Mattiace, S.H. Yen, and C. Brosnan Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease Glia 7 1993 75 83
12. S.W. Barger, and A.D. Harmon Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E Nature 388 1997 878 881
13. L.A. DeGiorgio, Y. Shimizu, H.S. Chun, Y.S. Kim, S. Sugama, J.H. Son, and et al. Amyloid precursor protein gene disruption attenuates degeneration of substantia nigra compacta neurons following axotomy Brain Res 938 2002 38 44
14. P.L. McGeer, and E.G. McGeer Glial reactions in Parkinson's disease Mov Disord 23 2008 474 483
15. X.D. Pan, Y.G. Zhu, N. Lin, J. Zhang, Q.Y. Ye, H.P. Huang, and et al. Microglial phagocytosis induced by fibrillar beta-amyloid is attenuated by oligomeric beta-amyloid: implications for Alzheimer's disease Mol Neurodegener 6 2011 45
16. H.M. Wisniewski, J. Wegiel, K.C. Wang, M. Kujawa, and B. Lach Ultrastructural studies of the cells forming amyloid fibers in classical plaques Can J Neurol Sci 16 1989 535 542
17. H.M. Wisniewski, J. Wegiel, K.C. Wang, and B. Lach Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease Acta Neuropathol (Berl) 84 1992 117 127
18. T. Wisniewski, M. Haltia, J. Ghiso, and B. Frangione Lewy bodies are immunoreactive with antibodies raised to gelsolin related amyloid-Finnish type Am J Pathol 138 1991 1077 1083
19. J. Rogers, L.F. Lue, D.G. Walker, S.D. Yan, D. Stern, R. Strohmeyer, and et al. Elucidating molecular mechanisms of Alzheimer's disease in microglial cultures Ernst Schering Res Found Workshop 2002 25 44
20. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, and et al. Inflammation and Alzheimer's disease Neurobiol Aging 21 2000 383 421
21. E. Zotova, V. Bharambe, M. Cheaveau, W. Morgan, C. Holmes, S. Harris, and et al. Inflammatory components in human Alzheimer's disease and after active amyloid-beta42 immunization Brain 136 2013 2677 2696
22. D.M. Mosser, and J.P. Edwards Exploring the full spectrum of macrophage activation Nat Rev Immunol 8 2008 958 969
23. W.S. Griffin, J.G. Sheng, G.W. Roberts, and R.E. Mrak Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution J Neuropathol Exp Neurol 54 1995 276 281
24. R. Guerreiro, A. Wojtas, J. Bras, M. Carrasquillo, E. Rogaeva, E. Majounie, and et al. TREM2 variants in Alzheimer's disease N Engl J Med 368 2013 117 127
25. R.B. Banati Visualising microglial activation in vivo Glia 40 2002 206 217
26. R.B. Banati, J. Newcombe, R.N. Gunn, A. Cagnin, F. Turkheimer, F. Heppner, and et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity Brain 123 Pt 11 2000 2321 2337
27. A. Martin, R. Boisgard, B. Theze, N. Van Camp, B. Kuhnast, A. Damont, and et al. Evaluation of the PBR/TSPO radioligand [(18)F]DPA-714 in a rat model of focal cerebral ischemia J Cereb Blood Flow Metab 30 2010 230 241
28. S. Venneti, G. Wang, J. Nguyen, and C.A. Wiley The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders J Neuropathol Exp Neurol 67 2008 1001 1010
29. S. Lavisse, M. Guillermier, A.S. Herard, F. Petit, M. Delahaye, N. Van Camp, and et al. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging J Neurosci 32 2012 10809 10818
30. B. Ji, J. Maeda, M. Sawada, M. Ono, T. Okauchi, M. Inaji, and et al. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies J Neurosci 28 2008 12255 12267
31. S. Rojas, A. Martin, M.J. Arranz, D. Pareto, J. Purroy, E. Verdaguer, and et al. Imaging brain inflammation with [(11)C]PK11195 by PET and induction of the peripheral-type benzodiazepine receptor after transient focal ischemia in rats J Cereb Blood Flow Metab 27 2007 1975 1986
32. P. Charbonneau, A. Syrota, C. Crouzel, J.M. Valois, C. Prenant, and M. Crouzel Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography Circulation 73 1986 476 483
33. S. Venneti, B.J. Lopresti, G. Wang, R.L. Hamilton, C.A. Mathis, W.E. Klunk, and et al. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET Neurobiol Aging 30 2009 1217 1226
34. S.A. Frautschy, F. Yang, M. Irrizarry, B. Hyman, T.C. Saido, K. Hsiao, and et al. Microglial response to amyloid plaques in APPsw transgenic mice Am J Pathol 152 1998 307 317
35. A. Cagnin, D.J. Brooks, A.M. Kennedy, R.N. Gunn, R. Myers, F.E. Turkheimer, and et al. In-vivo measurement of activated microglia in dementia Lancet 358 2001 461 467
36. P. Edison, H.A. Archer, A. Gerhard, R. Hinz, N. Pavese, F.E. Turkheimer, and et al. Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study Neurobiol Dis 32 2008 412 419
37. A. Okello, P. Edison, H.A. Archer, F.E. Turkheimer, J. Kennedy, R. Bullock, and et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study Neurology 72 2009 56 62
38. C.A. Wiley, B.J. Lopresti, S. Venneti, J. Price, W.E. Klunk, S.T. DeKosky, and et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease Arch Neurol 66 2009 60 67
39. I. Napoli, and H. Neumann Microglial clearance function in health and disease Neuroscience 158 2009 1030 1038
40. T. Bolmont, F. Haiss, D. Eicke, R. Radde, C.A. Mathis, W.E. Klunk, and et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance J Neurosci 28 2008 4283 4292
41. J. Koenigsknecht-Talboo, and G.E. Landreth Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines J Neurosci 25 2005 8240 8249
42. M. Politis, P. Su, and P. Piccini Imaging of microglia in patients with neurodegenerative disorders Front Pharmacol 3 2012 96
43. A. Cagnin, M. Rossor, E.L. Sampson, T. Mackinnon, and R.B. Banati In vivo detection of microglial activation in frontotemporal dementia Ann Neurol 56 2004 894 897
44. S. Iannaccone, C. Cerami, M. Alessio, V. Garibotto, A. Panzacchi, S. Olivieri, and et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease Parkinsonism Relat Disord 19 2013 47 52
45. I.G. McKeith, D.W. Dickson, J. Lowe, M. Emre, J.T. O'Brien, H. Feldman, and et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology 65 2005 1863 1872
46. S. Kim, M. Moon, and S. Park Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease J Endocrinol 202 2009 431 439
47. W. Zhang, T. Wang, Z. Pei, D.S. Miller, X. Wu, M.L. Block, and et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease FASEB J 19 2005 533 542
48. Y. Ouchi, E. Yoshikawa, Y. Sekine, M. Futatsubashi, T. Kanno, T. Ogusu, and et al. Microglial activation and dopamine terminal loss in early Parkinson's disease Ann Neurol 57 2005 168 175
49. A.L. Bartels, A.T. Willemsen, J. Doorduin, E.F. de Vries, R.A. Dierckx, and K.L. Leenders [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat Disord 16 2010 57 59
50. A. Gerhard, N. Pavese, G. Hotton, F. Turkheimer, M. Es, A. Hammers, and et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease Neurobiol Dis 21 2006 404 412
51. H. Braak, K. Del Tredici, U. Rub, R.A. de Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 2003 197 211
52. A. Gerhard, R.B. Banati, G.B. Goerres, A. Cagnin, R. Myers, R.N. Gunn, and et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy Neurology 61 2003 686 689
53. A. Gerhard, I. Trender-Gerhard, F. Turkheimer, N.P. Quinn, K.P. Bhatia, and D.J. Brooks In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy Mov Disord 21 2006 89 93
54. A. Gerhard, J. Watts, I. Trender-Gerhard, F. Turkheimer, R.B. Banati, K. Bhatia, and et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration Mov Disord 19 2004 1221 1226
55. R. Dodel, A. Spottke, A. Gerhard, A. Reuss, S. Reinecker, N. Schimke, and et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial) Mov Disord 25 2010 97 107
56. S.J. Tabrizi, D.R. Langbehn, B.R. Leavitt, R.A. Roos, A. Durr, D. Craufurd, and et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data Lancet Neurol 8 2009 791 801
57. J.P. Vonsattel, R.H. Myers, T.J. Stevens, R.J. Ferrante, E.D. Bird, and E.P. Richardson Jr. Neuropathological classification of Huntington's disease J Neuropathol Exp Neurol 44 1985 559 577
58. N. Pavese, A. Gerhard, Y.F. Tai, A.K. Ho, F. Turkheimer, R.A. Barker, and et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study Neurology 66 2006 1638 1643
59. Y.F. Tai, N. Pavese, A. Gerhard, S.J. Tabrizi, R.A. Barker, D.J. Brooks, and et al. Imaging microglial activation in Huntington's disease Brain Res Bull 72 2007 148 151
60. M. Politis, N. Pavese, Y.F. Tai, L. Kiferle, S.L. Mason, D.J. Brooks, and et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study Hum Brain Mapp 32 2011 258 270
61. G.W. Price, R.G. Ahier, S.P. Hume, R. Myers, L. Manjil, J.E. Cremer, and et al. In vivo binding to peripheral benzodiazepine binding sites in lesioned rat brain: comparison between [3H]PK11195 and [18F]PK14105 as markers for neuronal damage J Neurochem 55 1990 175 185
62. R.N. Gunn, S.R. Gunn, and V.J. Cunningham Positron emission tomography compartmental models J Cereb Blood Flow Metab 21 2001 635 652
63. M.A. Kropholler, R. Boellaard, A. Schuitemaker, H. Folkersma, B.N. van Berckel, and A.A. Lammertsma Evaluation of reference tissue models for the analysis of [11C](R)-PK11195 studies J Cereb Blood Flow Metab 26 2006 1431 1441
64. F.E. Turkheimer, P. Edison, N. Pavese, F. Roncaroli, A.N. Anderson, A. Hammers, and et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies J Nucl Med 48 2007 158 167
65. M. Yaqub, B.N. van Berckel, A. Schuitemaker, R. Hinz, F.E. Turkheimer, G. Tomasi, and et al. Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[(11)C]PK11195 brain PET studies J Cereb Blood Flow Metab 32 2012 1600 1608
66. W.C. Kreisl, M. Fujita, Y. Fujimura, N. Kimura, K.J. Jenko, P. Kannan, and et al. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker Neuroimage 49 2010 2924 2932
67. D.R. Owen, R.N. Gunn, E.A. Rabiner, I. Bennacef, M. Fujita, W.C. Kreisl, and et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands J Nucl Med 52 2011 24 32
68. D.R. Owen, A.J. Yeo, R.N. Gunn, K. Song, G. Wadsworth, A. Lewis, and et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 J Cereb Blood Flow Metab 32 2012 1 5
69. D.R. Owen, O.W. Howell, S.P. Tang, L.A. Wells, I. Bennacef, M. Bergstrom, and et al. Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation J Cereb Blood Flow Metab 30 2010 1608 1618
70. V.W. Pike, S. Taliani, T.G. Lohith, D.R. Owen, I. Pugliesi, E. Da Pozzo, and et al. Evaluation of novel N1-methyl-2-phenylindol-3-ylglyoxylamides as a new chemotype of 18 kDa translocator protein-selective ligand suitable for the development of positron emission tomography radioligands J Med Chem 54 2011 366 373
71. A. Damont, R. Boisgard, B. Kuhnast, F. Lemee, G. Raggiri, A.M. Scarf, and et al. Synthesis of 6-[(1)(8)F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET Bioorg Med Chem Lett 21 2011 4819 4822
72. W.C. Kreisl, C.H. Lyoo, M. McGwier, J. Snow, K.J. Jenko, N. Kimura, and et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease Brain 136 2013 2228 2238
73. J. Maeda, T. Suhara, M.R. Zhang, T. Okauchi, F. Yasuno, Y. Ikoma, and et al. Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: an imaging tool for glial cells in the brain Synapse 52 2004 283 291
74. F. Yasuno, J. Kosaka, M. Ota, M. Higuchi, H. Ito, Y. Fujimura, and et al. Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [(1)(1)C]DAA1106 Psychiatry Res 203 2012 67 74
75. F. Yasuno, M. Ota, J. Kosaka, H. Ito, M. Higuchi, T.K. Doronbekov, and et al. Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106 Biol Psychiatry 64 2008 835 841
76. A. Takano, R. Arakawa, H. Ito, A. Tateno, H. Takahashi, R. Matsumoto, and et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106 Int J Neuropsychopharmacol 13 2010 943 950
77. N. Arlicot, J. Vercouillie, M.J. Ribeiro, C. Tauber, Y. Venel, J.L. Baulieu, and et al. Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation Nucl Med Biol 39 2012 570 578
78. P. Corcia, C. Tauber, J. Vercoullie, N. Arlicot, C. Prunier, J. Praline, and et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis PLoS One 7 2012 e52941
79. B. Gulyas, C. Halldin, J. Sovago, J. Sandell, Z. Cselenyi, A. Vas, and et al. Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine Eur J Nucl Med Mol Imaging 29 2002 1031 1038
80. B. Gulyas, C. Halldin, A. Vas, R.B. Banati, E. Shchukin, S. Finnema, and et al. [11C]vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies J Neurol Sci 229-230 2005 219 223
81. A. Vas, Y. Shchukin, V.D. Karrenbauer, Z. Cselenyi, K. Kostulas, J. Hillert, and et al. Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients J Neurol Sci 264 2008 9 17
82. B. Gulyas, A. Vas, M. Toth, A. Takano, A. Varrone, Z. Cselenyi, and et al. Age and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with [11C]vinpocetine Neuroimage 56 2011 1111 1121
83. B. Gulyas, M. Toth, M. Schain, A. Airaksinen, A. Vas, K. Kostulas, and et al. Evolution of microglial activation in ischaemic core and peri-infarct regions after stroke: a PET study with the TSPO molecular imaging biomarker [((11))C]vinpocetine J Neurol Sci 320 2012 110 117
84. E.S. Onaivi Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain Neuropsychobiology 54 2006 231 246
85. K. Maresz, E.J. Carrier, E.D. Ponomarev, C.J. Hillard, and B.N. Dittel Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli J Neurochem 95 2005 437 445
86. J.L. Shoemaker, K.A. Seely, R.L. Reed, J.P. Crow, and P.L. Prather The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset J Neurochem 101 2007 87 98
87. J.C. Ashton, R.M. Rahman, S.M. Nair, B.A. Sutherland, M. Glass, and I. Appleton Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain Neurosci Lett 412 2007 114 117
88. B.G. Ramirez, C. Blazquez, T. Gomez del Pulgar, M. Guzman, and M.L. de Ceballos Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation J Neurosci 25 2005 1904 1913
89. N. Evens, C. Vandeputte, C. Coolen, P. Janssen, R. Sciot, V. Baekelandt, and et al. Preclinical evaluation of [11C]NE40, a type 2 cannabinoid receptor PET tracer Nucl Med Biol 39 2012 389 399
90. N. Evens, C. Vandeputte, G.G. Muccioli, D.M. Lambert, V. Baekelandt, A.M. Verbruggen, and et al. Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging Bioorg Med Chem 19 2011 4499 4505
91. A.G. Horti, Y. Gao, H.T. Ravert, P. Finley, H. Valentine, D.F. Wong, and et al. Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2) Bioorg Med Chem 18 2010 5202 5207
92. D.L. Simmons, R.M. Botting, and T. Hla Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition Pharmacol Rev 56 2004 387 437
93. S.H. Choi, S. Aid, and F. Bosetti The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research Trends Pharmacol Sci 30 2009 174 181
94. M. Shukuri, M. Takashima-Hirano, K. Tokuda, T. Takashima, K. Matsumura, O. Inoue, and et al. In vivo expression of cyclooxygenase-1 in activated microglia and macrophages during neuroinflammation visualized by PET with 11C-ketoprofen methyl ester J Nucl Med 52 2011 1094 1101
95. K.S. Montine, J.F. Quinn, J. Zhang, J.P. Fessel, L.J. Roberts 2nd, J.D. Morrow, and et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases Chem Phys Lipids 128 2004 117 124
96. G. Giovacchini, A. Lerner, M.T. Toczek, C. Fraser, K. Ma, J.C. DeMar, and et al. Brain incorporation of 11C-arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction J Nucl Med 45 2004 1471 1479
97. G. Esposito, G. Giovacchini, J.S. Liow, A.K. Bhattacharjee, D. Greenstein, M. Schapiro, and et al. Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET J Nucl Med 49 2008 1414 1421
98. 11C]A-740003 as a novel tracer of neuroinflammation J Labelled Comp Radiopharm 57 2014 506 516
99. N. Matusiak, A. van Waarde, R. Bischoff, R. Oltenfreiter, C. van de Wiele, R.A. Dierckx, and et al. Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT Curr Pharm Des 25 2013 4647 4672
100. B. Gulyas, E. Pavlova, P. Kasa, K. Gulya, L. Bakota, S. Varszegi, and et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography Neurochem Int 58 2011 60 68
101. J. Saura, J.M. Luque, A.M. Cesura, M. Da Prada, V. Chan-Palay, G. Huber, and et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography Neuroscience 62 1994 15 30
102. T. Marshall, P. Shult, and W.W. Busse Release of lysosomal enzyme beta-glucuronidase from isolated human eosinophils J Allergy Clin Immunol 82 1988 550 555
103. A.J. Cross, T.J. Crow, J.M. Dawson, I.N. Ferrier, J.A. Johnson, T.J. Peters, and et al. Subcellular pathology of human neurodegenerative disorders: Alzheimer-type dementia and Huntington's disease J Neurochem 47 1986 882 889
104. E.G. McGeer, P.L. McGeer, R. Harrop, H. Akiyama, and H. Kamo Correlations of regional postmortem enzyme activities with premortem local glucose metabolic rates in Alzheimer's disease J Neurosci Res 27 1990 612 619
105. I.F. Antunes, J. Doorduin, H.J. Haisma, P.H. Elsinga, A. van Waarde, A.T. Willemsen, and et al. 18F-FEAnGA for PET of beta-glucuronidase activity in neuroinflammation J Nucl Med 53 2012 451 458
106. M. Wideroe, C. Brekken, A. Kavelaars, T.B. Pedersen, P.E. Goa, C. Heijnen, and et al. Longitudinal manganese-enhanced magnetic resonance imaging of delayed brain damage after hypoxic-ischemic injury in the neonatal rat Neonatology 100 2011 363 372
107. C. Wang, P.B. Gordon, S.O. Hustvedt, D. Grant, A.T. Sterud, I. Martinsen, and et al. MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers Acta Radiol 38 1997 665 676
108. E. Cerutti, A. Damont, F. Dolle, S. Baroni, and S. Aime Synthesis and characterization of an MRI Gd-based probe designed to target the translocator protein Magn Reson Chem 51 2013 116 122
109. N. Sailasuta, K. Harris, T. Tran, and B. Ross Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study Neuropsychiatr Dis Treat 7 2011 495 499
110. D. Jaturapatporn, M.G. Isaac, J. McCleery, and N. Tabet Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease Cochrane Database Syst Rev 2 2012 CD006378
111. N.R. Relkin, P. Szabo, B. Adamiak, T. Burgut, C. Monthe, R.W. Lent, and et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease Neurobiol Aging 30 2009 1728 1736
112. R.C. Dodel, Y. Du, C. Depboylu, H. Hampel, L. Frolich, A. Haag, and et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease J Neurol Neurosurg Psychiatry 75 2004 1472 1474
113. R. Dodel, A. Rominger, P. Bartenstein, F. Barkhof, K. Blennow, S. Forster, and et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial Lancet Neurol 12 2013 233 243
114. Baxter US. Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease. 2013. Available at http://www.baxter.com/press-room/press-releases/2013/05-07-13-gap-study.html. Accessed November 1, 2014.
115. Grifols Biologicals Inc. A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease (AMBAR). 2013. Available at: http://clinicaltrials.gov/show/NCT01561053. Accessed November 1, 2014.
116. Sutter Health. Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment (MCI). 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01300728. Accessed November 1, 2014.
117. E. Tobinick, H. Gross, A. Weinberger, and H. Cohen TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study MedGenMed 8 2006 25
118. Life Extension Foundation Inc. Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease. 2013. Available at: http://clinicaltrials.gov/show/NCT01716637. Accessed November 1, 2014.